Anzeige
Mehr »
Login
Samstag, 02.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Technischer Ausbruch: Diese Kupferaktie ist in den letzten 52 Wochen um 300 % gestiegen! Der Durchbruch läuft!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JV3R | ISIN: US3632252025 | Ticker-Symbol: PHPN
Frankfurt
01.11.24
21:49 Uhr
2,200 Euro
-0,040
-1,79 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
GALECTIN THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
GALECTIN THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
2,2402,38013:05
2,2402,38001.11.

Aktuelle News zur GALECTIN THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
23.10.Galectin Therapeutics Direktor Eldred Kary kauft Aktien im Wert von 1.300 US-Dollar1
17.10.Insider Buying: Galectin Therapeutics Inc. (NASDAQ:GALT) Director Purchases 5,000 Shares of Stock1
16.10.Galectin Therapeutics Inc. (NASDAQ:GALT) Director Purchases $13,500.00 in Stock1
15.10.Galectin Therapeutics Inc.: Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting1
09.09.GALECTIN THERAPEUTICS INC - 8-K, Current Report2
03.09.Galectin Therapeutics Inc.: Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference1
13.08.Galectin Flat on Quarterly Figures-
13.08.Galectin Therapeutics GAAP EPS of -$0.201
13.08.Galectin Therapeutics Inc reports results for the quarter ended in June - Earnings Summary1
13.08.Galectin Therapeutics Inc.: Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update76NAVIGATE trial on track for interim top-line analysis in December 2024 NORCROSS, Ga., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics...
► Artikel lesen
13.08.GALECTIN THERAPEUTICS INC - 8-K, Current Report-
13.08.GALECTIN THERAPEUTICS INC - 10-Q, Quarterly Report-
09.08.Galectin Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview1
01.08.Galectin Therapeutics appoints Khurram Jamil as chief medical officer2
01.08.Galectin Therapeutics Inc.: Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer111NORCROSS, Ga., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of...
► Artikel lesen
01.08.GALECTIN THERAPEUTICS INC - 8-K, Current Report1
04.06.Galectin Therapeutics Inc.: Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress3
03.06.FibroGen, Inc.: FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors202The safety and efficacy of FG-3165 will be evaluated in a Phase 1 trial in select solid tumorsPlan to begin enrollment in 2H 2024 SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:...
► Artikel lesen
15.05.Galectin Therapeutics GAAP EPS of -$0.191
15.05.Galectin Therapeutics Inc.: Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update138Fifth Data and Safety Monitoring Board (DSMB) meeting recommended the continuation, without modifications, of the Phase 2b/3 NAVIGATE study of belapectin in liver cirrhosis due to metabolic dysfunction-associated...
► Artikel lesen
Seite:  Weiter >>
26 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1